Investors might want to bet on Repligen (RGEN - Free Report) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.
Analysts' growing optimism on the earnings prospects of this drug developer is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Repligen, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate Revisions
The earnings estimate of $0.28 per share for the current quarter represents a change of -9.68% from the number reported a year ago.
Over the last 30 days, the Zacks Consensus Estimate for Repligen has increased 8.24% because four estimates have moved higher while two have gone lower.
Current-Year Estimate Revisions
For the full year, the earnings estimate of $1.11 per share represents a change of +3.74% from the year-ago number.
There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, seven estimates have moved up for Repligen versus one negative revision. This has pushed the consensus estimate 8.24% higher.
Favorable Zacks Rank
Thanks to promising estimate revisions, Repligen currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Repligen shares have added 22.4% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.